For example, estrogen receptor modulators/agonists targeting ESR1 are now used in the clinic; this includes bazedoxifene acetate and conjugated estrogens for preventing postmenopausal osteoporosis (related to oestrogen deficiency) (67). This evidence concerns the gene ESR1 and postmenopausal osteoporosis.